Factor Xa inhibition for the treatment of venous thromboembolism associated with cancer: a meta-analysis of the randomised controlled trials
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
AC Murphy, AN Koshy, O Farouque, B Yeo, J Raman… - 2022 - ahro.austin.org.au
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer
patients. Until recently, guidelines recommended the use of low-molecular weight heparin …
patients. Until recently, guidelines recommended the use of low-molecular weight heparin …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials
AC Murphy, AN Koshy, O Farouque, B Yeo… - Heart, Lung and …, 2022 - heartlungcirc.org
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials
AC Murphy, AN Koshy, O Farouque… - Heart, lung & …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
[PDF][PDF] Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials
AC Murphy, AN Koshy, O Farouque, B Yeo… - Heart, Lung and …, 2022 - drive.google.com
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
AC Murphy, AN Koshy, O Farouque, B Yeo… - Heart, Lung & …, 2021 - europepmc.org
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
AC Murphy, AN Koshy, O Farouque, B Yeo, J Raman… - 2022 - austin.intersearch.com.au
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer
patients. Until recently, guidelines recommended the use of low-molecular weight heparin …
patients. Until recently, guidelines recommended the use of low-molecular weight heparin …
Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials
AC Murphy, AN Koshy, O Farouque, B Yeo… - Heart, Lung and …, 2022 - heartlungcirc.org
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …